Recce Pharmaceuticals

Gold Sponsor

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering a New Class of Broad-Spectrum Synthetic Antibiotics. Designed to address the global health threat of antibiotic resistant superbugs, RECCE antibiotics continues to work, even with repeated use.

 

Lead candidate RECCE® 327 has been developed for the treatment of sepsis derived from E. coli and S. aureus bacteria as well as multi-drug resistant bacterial infections. The FDA has awarded RECCE® 327 QIDP designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.




GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


Joseph Sica

joseph.sica@terrapinn.com
+1 860.508.6307

 

 

Press & Media Partnerships

 


Molly Paprota
molly.paprota@terrapinn.com
+1 646.619.1815

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784